A recent study presented at the American Society of Clinical Oncology (ASCO) annual meeting has revealed that women using GLP-1 medications, such as Ozempic and Mounjaro, may experience a significant reduction in breast cancer risk. Specifically, the research indicates that these women are approximately 30% less likely to develop breast cancer, regardless of various factors like age and body mass index.
This finding is particularly noteworthy as it suggests that GLP-1 medications, primarily designed for weight loss and metabolic health, could play a role in cancer prevention. The drugs work by mimicking gut hormones that regulate insulin and appetite, which may also influence inflammation—a key factor in cancer development.
The implications of this study extend beyond individual health, potentially reshaping how healthcare providers approach weight management and cancer prevention strategies. As breast cancer remains one of the most prevalent cancers among women, integrating these medications into broader health interventions could lead to significant public health benefits.
However, the study’s observational nature means further research is necessary to confirm these findings. Researchers are advocating for randomized trials to explore the potential of GLP-1 drugs not only in reducing cancer risk but also in addressing heart disease and menopause-related symptoms, highlighting a multifaceted approach to women’s health.
Source: Euronews
